Prefilled autoinfusion device

WO2026143138A1PCT designated stage Publication Date: 2026-07-02HALOZYME INC

Patent Information

Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner: HALOZYME INC
Filing Date: 2025-12-23
Publication Date: 2026-07-02

AI Technical Summary

Technical Problem

Current autoinfusion devices are limited to low flow rates, making them impractical for delivering high volumes of biologics, which often require larger doses.

Method used

A high-volume autoinfusion device with a starting delivery force of 5 lbf to 50 lbf, ending delivery force of 3 lbf to 20 lbf, starting pressure of 50 psi to 200 psi, and ending pressure of 20 psi to 75 psi is used to administer formulations containing hyaluronidase enzyme for subcutaneous delivery of active ingredients like small molecules, peptides, biologics, or nanoparticles.

Benefits of technology

The device enables efficient delivery of formulations at higher flow rates, reducing administration time, minimizing side effects, and improving patient comfort by using a prefilled syringe with a hyaluronidase enzyme to enhance delivery efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

Figure US2025061170_02072026_PF_FP_ABST

Patent Text Reader

Abstract

In one aspect, the present disclosure provides a prefilled autoinfusion device for delivery of a medicament comprising hyaluronidase. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject via a profiled autoinfusion device.

Need to check novelty before this filing date? Find Prior Art